Focused On-demand Library for Schlafen family member 11

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q7Z7L1

UPID:

SLN11_HUMAN

Alternative names:

Alternative UPACC:

Q7Z7L1; E1P643; Q8N3S8; Q8N762; Q8TEE0

Background:

Schlafen family member 11 (SLFN11) is a pivotal protein that inhibits DNA replication, promoting cell death in response to DNA damage. It serves as a guardian of the genome, ensuring cellular integrity by eliminating cells with defective replication mechanisms. SLFN11 blocks stressed replication forks, leading to cell death. Additionally, it functions as an antiviral protein against retroviruses like HIV-1 by inhibiting viral protein synthesis through a unique mechanism involving tRNA binding.

Therapeutic significance:

Understanding the role of Schlafen family member 11 could open doors to potential therapeutic strategies. Its unique mechanism of action in both DNA damage response and antiviral defense positions SLFN11 as a promising target for developing treatments against cancer and viral infections.